Raashid Luqmani

• The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.

  Luqmani R. et al, (2016), Health technology assessment (Winchester, England), 20, 1 - 238

• Giant Cell Arteritis and Takayasu Arteritis: Are they a different spectrum of the same disease?

  O'Neill L. et al, (2015), Indian Journal of Rheumatology, 10, S11 - S21

• Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

  Robson JC. et al, (2015), The Journal of rheumatology, 42, 2204 - 2209

• The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study

  Luqmani R. et al, (2015), ARTHRITIS & RHEUMATOLOGY, 67

• Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink.

  Miller A. et al, (2015), Rheumatology (Oxford, England), 54, 1882 - 1889

• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

  Jones RB. et al, (2015), Annals of the rheumatic diseases, 74, 1178 - 1182

• Giant cell arteritis: Current treatment and management.

  Ponte C. et al, (2015), World journal of clinical cases, 3, 484 - 494

• Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink.

  Sammon CJ. et al, (2015), Pharmacoepidemiology and drug safety, 24, 504 - 509

• RHEUMATOID FACTOR TESTING IN SPANISH PRIMARY CARE COSTS (sic)1432 PER TRUE POSITIVE CASE OF RHEUMATOID ARTHRITIS; A STUDY USING ELECTRONIC DATA FROM THE INFORMATION SYSTEM FOR THE DEVELOPMENT OF RESEARCH IN PRIMARY CARE

  Morsley K. et al, (2015), RHEUMATOLOGY, 54, 67 - 67

• RE-APPRAISAL OF THE 1990 AMERICAN COLLEGE OF RHEUMATOLOGY CLASSIFICATION CRITERIA FOR SYSTEMIC VASCULITIS: ANALYSIS OF DATA FROM THE DIAGNOSTIC AND CLASSIFICATION CRITERIA IN VASCULITIS STUDY

  Seeliger B. et al, (2015), RHEUMATOLOGY, 54, 173 - 173

• PRELIMINARY ANALYSIS OF HISTOLOGICAL FINDINGS IN GCA BIOPSY-POSITIVE PATIENTS RECRUITED INTO A LARGE MULTICENTRE STUDY OF TEMPORAL ARTERY ULTRASOUND VERSUS BIOPSY IN THE DIAGNOSIS OF GIANT CELL ARTERITIS

  Singh S. et al, (2015), RHEUMATOLOGY, 54, 173 - 174

• PREDICTORS OF DELAY IN DIAGNOSIS OF GIANT CELL ARTERITIS AND ANTINEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED VASCULITIDES: ANALYSIS OF DATA FROM THE DIAGNOSTIC & CLASSIFICATION CRITERIA IN VASCULITIS STUDY

  Seeliger B. et al, (2015), RHEUMATOLOGY, 54, 172 - 173

• INCREASED RISK OF CEREBROVASCULAR AND CEREBROVASCULAR DISEASE OUTCOMES IN PATIENTS WITH GIANT CELL ARTERITIS INDEPENDENTLY ASSOCIATED WITH SOCIAL DEPRIVATION

  Robson JC. et al, (2015), RHEUMATOLOGY, 54, 171 - 171

• EARLY HALO SIGN FEATURES ON ULTRASOUND EXAMINATION OF TREATED PATIENTS WITH GIANT CELL ARTERITIS

  Serafim AS. et al, (2015), RHEUMATOLOGY, 54, 32 - 32

• Disease assessment in systemic vasculitis.

  Luqmani RA., (2015), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30 Suppl 1, i76 - i82

• DEVELOPMENT OF AUTOMATED CLINICAL VIGNETTES FOR BIRMINGHAM VASCULITIS ACTIVITY SCORE TRAINING USING DATA FROM DIAGNOSTIC AND CLASSIFICATION CRITERIA IN VASCULITIS STUDY

  Querin H. et al, (2015), RHEUMATOLOGY, 54, 170 - 171

• DEVELOPMENT OF AN ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME MEASURE: IDENTIFICATION OF SALIENT THEMES AND CANDIDATE QUESTIONNAIRE ITEM DEVELOPMENT

  Robson JC. et al, (2015), RHEUMATOLOGY, 54, 171 - 172

• CARDIOVASCULAR OUTCOMES ARE WORSE IN MICROSCOPIC POLYANGIITIS COMPARED WITH GRANULOMATOSIS WITH POLYANGIITIS: DATA FROM AN INCEPTION COHORT OF PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED SYSTEMIC VASCULITIS

  Mistry A. et al, (2015), RHEUMATOLOGY, 54, 169 - 169

• A NEGATIVE RHEUMATOID FACTOR RESULT IN PRIMARY CARE SIGNIFICANTLY DELAYS THE TIME TO DIAGNOSIS OF RHEUMATOID ARTHRITIS: A STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK

  Nightingale AL. et al, (2015), RHEUMATOLOGY, 54, 67 - 68

• A DIAGNOSTIC PROTOCOL FOR GIANT CELL ARTERITIS USING ULTRASOUND ASSESSMENT

  Piper J. et al, (2015), RHEUMATOLOGY, 54, 33 - 33

• Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.

  Robson J. et al, (2015), Rheumatology (Oxford, England), 54, 471 - 481

• Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts.

  Pagnoux C. et al, (2015), Clinical and experimental rheumatology, 33

• The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

  Robson JC. et al, (2015), Annals of the rheumatic diseases, 74, 129 - 135

• The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

  Robson JC. et al, (2015), ANNALS OF THE RHEUMATIC DISEASES, 74, 129 - 135

• Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

  Robson J. et al, (2015), Annals of the rheumatic diseases, 74, 177 - 184

• Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts

  Pagnoux C. et al, (2015), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 33, S77 - S83

• Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.

  Latimer NR. et al, (2014), PharmacoEconomics, 32, 1171 - 1183

• BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.

  Ntatsaki E. et al, (2014), Rheumatology (Oxford, England), 53, 2306 - 2309

• United Kingdom & Ireland Vasculitis Registry - Cross-Sectional Data on the First 1085 Patients

  Sznajd J. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S773 - S773

• Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application

  Sznajd J. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S773 - S774

• Preliminary Analysis of Histological Findings in GCA Biopsy Positive Patients.

  Singh S. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S347 - S348

• Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis.

  Serafim AS. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S349 - S349

• Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain

  Luqmani R. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S157 - S158

• Colour Doppler Ultrasonography Findings in Giant Cell Arteritis (GCA) and Their Relationship with Clinical Manifestations.

  Ponte C. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S348 - S348

• A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using Ultrasound Assessment.

  Piper J. et al, (2014), ARTHRITIS & RHEUMATOLOGY, 66, S403 - S403

• Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.

  Ponte C. et al, (2014), Clinical and experimental rheumatology, 32

• Vasculitis: an update.

  Luqmani RA., (2014), British journal of hospital medicine (London, England : 2005), 75, 432 - 439

• PAEDIATRIC VASCULITIS DAMAGE INDEX: A NEW TOOL FOR STANDARDISED DISEASE ASSESSMENT

  Dolezalova P. et al, (2014), ANNALS OF THE RHEUMATIC DISEASES, 73, 696 - 697

• DEVELOPMENT OF THE CLASSIFICATION CRITERIA FOR GIANT CELL ARTERITIS IN THE DIAGNOSTIC AND CLASSIFICATION CRITERIA FOR VASCULITIS STUDY: A PILOT STUDY USING A PANEL REVIEW METHODOLOGY

  Ponte C. et al, (2014), ANNALS OF THE RHEUMATIC DISEASES, 73, 555 - 555

• A DIAGNOSTIC PROTOCOL FOR GIANT CELL ARTERITIS (GCA) USING ULTRASOUND ASSESSMENT

  Piper JE. et al, (2014), ANNALS OF THE RHEUMATIC DISEASES, 73, 658 - 659

• REVIEW OF THE EXPERT PANEL METHODOLOGY IN THE DIAGNOSTIC AND CLASSIFICATION CRITERIA FOR VASCULITIS STUDY: A PILOT STUDY

  Pante C. et al, (2014), RHEUMATOLOGY, 53, 15 - 16

• Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.

  Basu N. et al, (2014), Rheumatology (Oxford, England), 53, 953 - 956

• UK & IRELAND VASCULITIS REGISTRY (UKIVAS): CROSS-SECTIONAL DATA ON THE FIRST 556 PATIENTS

  Sznajd J. et al, (2014), RHEUMATOLOGY, 53, 184 - 185

• STANDARIZATION OF DISEASE ASSESMENT IN SYSTEMIC VASCULITIS: USE OF A NOVEL WEB-BASED SOFTWARE TRAINING APPLICATION

  Sznajd J. et al, (2014), RHEUMATOLOGY, 53, 186 - 186

• SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR IS SELECTIVELY UPREGULATED IN PATIENTS WITH BIOPSY-PROVEN GIANT CELL ARTERITIS

  Morlet J. et al, (2014), RHEUMATOLOGY, 53, 188 - 188

• NEGATIVE RHEUMATOID FACTOR IN PRIMARY CARE DELAYS REFERRAL OF PATIENTS WITH RHEUMATOID ARTHRITIS

  Miller A. et al, (2014), RHEUMATOLOGY, 53, 29 - 29

• MEET THE EXPERTS: VASCULITIS

  Luqmani R., (2014), RHEUMATOLOGY, 53, 19 - 20

• Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.

  Bluett J. et al, (2014), The pharmacogenomics journal, 14, 171 - 175

• Current status of outcome measure development in vasculitis.

  Merkel PA. et al, (2014), The Journal of rheumatology, 41, 593 - 598

• The characterisation and determinants of quality of life in ANCA associated vasculitis.

  Basu N. et al, (2014), Annals of the rheumatic diseases, 73, 207 - 211

• State of the art in the treatment of systemic vasculitides.

  Luqmani RA., (2014), Frontiers in immunology, 5

• The systemically ill patient Chapter: The systemically ill patient

  Robson R. et al, (2013), Oxford Textbook of Rheumatology

• The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care

  Miller A. et al, (2013), ARTHRITIS AND RHEUMATISM, 65, S964 - S965

• Test Data in General Practice Are Not Missing at Random - Can We Identify When They Are?

  Sammon CJ. et al, (2013), PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 22, 305 - 306

• Review Of The Expert Panel Methodology In The Diagnostic and Classification Criteria For Vasculitis Study: A Pilot Study

  Ponte C. et al, (2013), ARTHRITIS AND RHEUMATISM, 65, S1192 - S1192

• Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides

  Robson J. et al, (2013), ARTHRITIS AND RHEUMATISM, 65, S315 - S315

• Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).

  Dolezalova P. et al, (2013), Annals of the rheumatic diseases, 72, 1628 - 1633

• Disease activity assessment in childhood vasculitis: Development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)

  Dolezalova P. et al, (2013), Annals of the Rheumatic Diseases, 72, 1628 - 1633

• Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis

  Mistry A. et al, (2013), ARTHRITIS AND RHEUMATISM, 65, S317 - S318

• Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update.

  Mahtani KR. et al, (2013), The British journal of general practice : the journal of the Royal College of General Practitioners, 63, 553 - 554

• ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

  Craven A. et al, (2013), Clinical and experimental nephrology, 17, 619 - 621

• Explaining fatigue in ANCA-associated vasculitis

  Basu N. et al, (2013), RHEUMATOLOGY, 52, 1680 - 1685

• Explaining fatigue in ANCA-associated vasculitis.

  Basu N. et al, (2013), Rheumatology (Oxford, England), 52, 1680 - 1685

• Is rheumatoid factor useful in primary care? A retrospective cross-sectional study

  Miller A. et al, (2013), Clinical Rheumatology, 32, 1089 - 1093

• Is rheumatoid factor useful in primary care? A retrospective cross-sectional study.

  Miller A. et al, (2013), Clinical rheumatology, 32, 1089 - 1093

• Discontinuation of therapies in vasculitis.

  Luqmani RA., (2013), Clinical and experimental rheumatology, 31, S93 - S97

• TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS

  Robson J. et al, (2013), RHEUMATOLOGY, 52, 171 - 171

• The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK

  Robson J. et al, (2013), PRESSE MEDICALE, 42, 672 - 673

• PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS

  Robson J. et al, (2013), RHEUMATOLOGY, 52, 149 - 150

• Markers for work disability in ANCA-associated vasculitis

  Basu N. et al, (2013), PRESSE MEDICALE, 42, 745 - 746

• FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS

  Robson J. et al, (2013), RHEUMATOLOGY, 52, 28 - 28

• Update on the classification of vasculitis.

  Waller R. et al, (2013), Best practice & research. Clinical rheumatology, 27, 3 - 17

• Opinion: Maintenance of clinical remission in ANCA-associated vasculitis

  Luqmani R., (2013), Nature Reviews Rheumatology, 9, 127 - 132

• Maintenance of clinical remission in ANCA-associated vasculitis.

  Luqmani R., (2013), Nature reviews. Rheumatology, 9, 127 - 132

• 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

  Jennette JC. et al, (2013), Arthritis and rheumatism, 65, 1 - 11

• Textbook of Orthopaedics, Trauma and Rheumatology

  Luqmani R. et al, (2012)

• Damage assessment in ANCA-associated vasculitis.

  Bhamra K. and Luqmani R., (2012), Current rheumatology reports, 14, 494 - 500

• 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

  Jennette JC. et al, (2012), Revmatologiia (Bulgaria), 20, 5 - 15

• Large vessel vasculitides: update for the cardiologist.

  Luqmani R., (2012), Current opinion in cardiology, 27, 578 - 584

• Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV).

  Basu N. et al, (2012), ARTHRITIS AND RHEUMATISM, 64, S653 - S653

• THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

  Yew S. et al, (2012), NEPHROLOGY, 17, 45 - 45

• Treat-to-target in vasculitis: is this a sensible approach?

  Luqmani RA., (2012), Clinical and experimental rheumatology, 30, S149 - S153

• THE RELATIONSHIP BETWEEN BRAIN WHITE MATTER CHANGES AND FATIGUE IN GRANULOMATOSIS WITH POLYANGIITIS (GPA; WEGENER'S)

  Basu N. et al, (2012), ANNALS OF THE RHEUMATIC DISEASES, 71, 385 - 386

• Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

  Harper L. et al, (2012), Annals of the rheumatic diseases, 71, 955 - 960

• CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)

  Basu N. et al, (2012), ANNALS OF THE RHEUMATIC DISEASES, 71, 95 - 95

• CLASSIFICATION AND DIAGNOSIS OF VASCULITIS

  Luqmani R., (2012), ANNALS OF THE RHEUMATIC DISEASES, 71, 17 - 17

• THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS

  Yew S. et al, (2012), NEPHROLOGY DIALYSIS TRANSPLANTATION, 27, 184 - 184

• Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations.

  Küker W. et al, (2012), Neuroradiology, 54, 529 - 532

• Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

  Guerry MJ. et al, (2012), Rheumatology (Oxford, England), 51, 634 - 643

• Patient-reported outcomes in polymyalgia rheumatica.

  Matteson EL. et al, (2012), The Journal of rheumatology, 39, 795 - 803

• 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

  Dasgupta B. et al, (2012), Arthritis and rheumatism, 64, 943 - 954

• 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

  Dasgupta B. et al, (2012), Annals of the rheumatic diseases, 71, 484 - 492

• Can we identify patients with microscopic polyangiitis who are at risk of relapse?

  Luqmani RA., (2012), The Journal of rheumatology, 39, 455 - 457

• The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis.

  Fuchs M. et al, (2012), European journal of nuclear medicine and molecular imaging, 39, 344 - 353

• NEW INSIGHTS INTO THE MANAGEMENT OF SYSTEMIC VASCULITIS

  Luqmani R., (2012), RHEUMATOLOGY, 51, I6 - I8

• Diagnosis and management of ANCA associated vasculitis.

  Berden A. et al, (2012), BMJ : British Medical Journal, 344

• The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target.

  Chakera A. et al, (2012), Clinical and Developmental Immunology, 2012

• Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides.

  Demirkaya E. et al, (2012), Clinical and experimental rheumatology, 30, S162 - S168

• Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.

  Suppiah R. et al, (2011), Rheumatology (Oxford, England), 50, 2214 - 2222

• Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials

  Suppiah R. et al, (2011), RHEUMATOLOGY, 50, 2214 - 2222

• BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis.

  Bukhari M. et al, (2011), Rheumatology (Oxford, England), 50, 2311 - 2313

• The Need for Diagnostic Criteria in Systemic Vasculitis

  Suppiah R. et al, (2011), Current Immunology Reviews, 7, 394 - 401

• Pulmonary-renal syndromes: an update for respiratory physicians.

  McCabe C. et al, (2011), Respiratory medicine, 105, 1413 - 1421

• Neural Correlates of Chronic Fatigue in Granulomatosis with Polyangiitis (GPA; Wegener's)-A Functional Magnetic Resonance Imaging (fMRI) Study

  Basu N. et al, (2011), ARTHRITIS AND RHEUMATISM, 63, S924 - S924

• Time to focus on outcome assessment tools for childhood vasculitis.

  Demirkaya E. et al, (2011), Pediatric rheumatology online journal, 9

• The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

  Merkel PA. et al, (2011), The Journal of rheumatology, 38, 1480 - 1486

• Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.

  Walsh M. et al, (2011), Arthritis care & research, 63, 1055 - 1061

• Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

  Direskeneli H. et al, (2011), The Journal of rheumatology, 38, 1471 - 1479

• The prognostic value of BVAS and VDI in ANCA-AAV

  Suppiah R. et al, (2011), CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 164, 121 - 121

• Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. A European, multi-centre randomized controlled trial: long-term follow-up

  Harper L. et al, (2011), CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 164, 56 - 57

• Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV

  Suppiah R. et al, (2011), CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 164, 121 - 121

• Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).

  Luqmani RA. et al, (2011), Clinical and experimental immunology, 164 Suppl 1, 11 - 13

• Long-term damage to the ENT system in Wegener's granulomatosis.

  Martinez Del Pero M. et al, (2011), European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 268, 733 - 739

• A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

  Suppiah R. et al, (2011), Rheumatology (Oxford, England), 50, 899 - 905

• THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS

  Suppiah R. et al, (2011), RHEUMATOLOGY, 50, 147 - 148

• Systemic vasculitis--is it time to reclassify?

  Watts RA. et al, (2011), Rheumatology (Oxford, England), 50, 643 - 645

• Mortality in Wegener's granulomatosis: a bimodal pattern.

  Luqmani R. et al, (2011), Rheumatology (Oxford, England), 50, 697 - 702

• Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis

  Falk RJ. et al, (2011), Arthritis Care and Research, 63, 863 - 864

• Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

  Falk RJ. et al, (2011), Arthritis and rheumatism, 63, 863 - 864

• Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

  Falk RJ. et al, (2011), Journal of the American Society of Nephrology : JASN, 22, 587 - 588

• Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.

  Falk RJ. et al, (2011), Annals of the rheumatic diseases, 70

• DIAGNOSIS AND ASSESSMENT OF LARGE VESSEL VASCULITIS

  Luqmani R., (2011), RHEUMATOLOGY, 50, 24 - 24

• A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

  Suppiah R. et al, (2011), Arthritis care & research, 63, 588 - 596

• A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULOMATOSIS AND MICROSCOPIC POLYANGIITIS

  Suppiah R. et al, (2011), RHEUMATOLOGY, 50, 148 - 148

• Long-term patient survival in ANCA-associated vasculitis.

  Flossmann O. et al, (2011), Annals of the rheumatic diseases, 70, 488 - 494

• A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis.

  Suppiah R. et al, (2011), Arthritis Care Res (Hoboken)

• Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

  Suppiah R. et al, (2011), Annals of the rheumatic diseases, 70, 80 - 85

• BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.

  Ding T. et al, (2010), Rheumatology (Oxford, England), 49, 2217 - 2219

• EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.

  Basu N. et al, (2010), Annals of the rheumatic diseases, 69, 1744 - 1750

• Outcome measures in ANCA-associated vasculitis.

  Suppiah R. et al, (2010), Rheumatic diseases clinics of North America, 36, 587 - 607

• Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.

  Arnold DF. et al, (2010), Journal of Clinical Pathology, 63, 678 - 680

• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

  Jones RB. et al, (2010), The New England journal of medicine, 363, 211 - 220

• BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy.

  Deighton C. et al, (2010), Rheumatology (Oxford, England), 49, 1197 - 1199

• An approach to the diagnosis and management of systemic vasculitis.

  Miller A. et al, (2010), Clinical and experimental immunology, 160, 143 - 160

• RHEUMATOID FACTOR SHOULD NOT BE USED AS A SCREENING TOOL IN PRIMARY CARE

  Miller A. et al, (2010), RHEUMATOLOGY, 49, I68 - I68

• MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA)

  Suppiah R. et al, (2010), RHEUMATOLOGY, 49, I124 - I124

• A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULMOATOSIS AND MICROSCOPIC POLYANGIITIS

  Suppiah R. et al, (2010), RHEUMATOLOGY, 49, I124 - I124

• ANCA-associated vasculitis: Where can we go from here?

  Luqmani R., (2010), SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 39, 13 - 13

• Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

  Mukhtyar C. et al, (2009), Annals of the rheumatic diseases, 68, 1827 - 1832

• Advances in the classification of primary systemic vasculitis

  Suppiah R. et al, (2009), International Journal of Advances in Rheumatology, 7, 10 - 18

• Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

  Merkel PA. et al, (2009), The Journal of rheumatology, 36, 2362 - 2368

• Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.

  Flossmann O. et al, (2009), Annals of the rheumatic diseases, 68, 1125 - 1130

• Assessment of damage in vasculitis: expert ratings of damage.

  Seo P. et al, (2009), Rheumatology (Oxford, England), 48, 823 - 827

• Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis

  Luqmani R. et al, (2009), APMIS, 117, 115 - 115

• Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS

  Jones R. et al, (2009), APMIS, 117, 78 - 78

• Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial

  Harper L. et al, (2009), APMIS, 117, 77 - 77

• Pharmacotherapy of vasculitis.

  Chan M. and Luqmani R., (2009), Expert opinion on pharmacotherapy, 10, 1273 - 1289

• Long-term survival of ANCA-associated vasculitis

  Flossmann O. et al, (2009), APMIS, 117, 139 - 139

• Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials

  Walsh M. et al, (2009), APMIS, 117, 138 - 138

• Cardiovascular involvement in primary systemic vasculitis.

  Mukhtyar C. et al, (2009), Best practice & research. Clinical rheumatology, 23, 419 - 428

• Bimodal mortality risk in Wegener's granulomatosis

  Luqmani R. et al, (2009), APMIS, 117, 160 - 160

• Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

  de Groot K. et al, (2009), Annals of internal medicine, 150, 670 - 680

• USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS

  Mukhtyar C. et al, (2009), RHEUMATOLOGY, 48, I16 - I17

• British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).

  Luqmani R. et al, (2009), Rheumatology (Oxford, England), 48, 436 - 439

• BIMODAL MORTALITY RISK IN WEGENER'S GRANULOMATOSIS

  Luqmani RA. et al, (2009), RHEUMATOLOGY, 48, I16 - I16

• ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS?

  Soni A. et al, (2009), RHEUMATOLOGY, 48, I41 - I42

• EULAR recommendations for the management of primary small and medium vessel vasculitis.

  Mukhtyar C. et al, (2009), Annals of the rheumatic diseases, 68, 310 - 317

• EULAR recommendations for the management of large vessel vasculitis.

  Mukhtyar C. et al, (2009), Annals of the rheumatic diseases, 68, 318 - 323

• Pleural Wegener's granulomatosis: a rare presentation.

  Faratian D. et al, (2009), Histopathology, 54, 391 - 393

• Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.

  Merkel PA. et al, (2009), Annals of the rheumatic diseases, 68, 103 - 106

• Assessment of systemic vasculitis.

  Miller A. et al, (2008), Autoimmunity reviews, 8, 170 - 175

• Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthoplasties: evidence for a type IV immune response.

  Pandit H. et al, (2008), Virchows Archiv : an international journal of pathology, 453, 529 - 534

• Validation of a new version of the Birmingbam vasculitis activity score

  Mukhtyar C. et al, (2008), ARTHRITIS AND RHEUMATISM, 58, S847 - S848

• Mortality in systemic vasculitis: a systematic review.

  Phillip R. and Luqmani R., (2008), Clinical and experimental rheumatology, 26, S94 - 104

• Cardiovascular outcomes in ANCA associated vasculitis

  Mukhtyar C. et al, (2008), ARTHRITIS AND RHEUMATISM, 58, S848 - S848

• Assessment of damage in vasculitis: Expert ratings of damage

  Seo P. et al, (2008), ARTHRITIS AND RHEUMATISM, 58, S852 - S852

• Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

  Mukhtyar C. et al, (2008), Annals of the rheumatic diseases, 67, 1004 - 1010

• Developing multidisciplinary guidelines for the management of early rheumatoid arthritis.

  Hennell S. and Luqmani R., (2008), Musculoskeletal care, 6, 97 - 107

• Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis

  Mukhtyar C. and Luqmani RA., (2008), RHEUMATOLOGY, 47, II100 - II100

• The value of a biologics clinic: Adherence to the BSR guidelines for the use of anti-TNF alpha therapy in rheumatoid arthritis

  MacDougall-Davis S. et al, (2008), RHEUMATOLOGY, 47, II31 - II31

• Safety of fast track infliximab infusions "the quick inflix''

  Jess C. et al, (2008), RHEUMATOLOGY, 47, II36 - II37

• Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)

  Mukhtyar C. et al, (2008), RHEUMATOLOGY, 47, II7 - II7

• An audit of an emergency rheumatology clinic have we improved our service?

  Wong E. et al, (2008), RHEUMATOLOGY, 47, II107 - II107

• Development of comprehensive disease assessment in systemic vasculitis.

  Flossmann O. et al, (2008), Postgraduate medical journal, 84, 143 - 152

• Tumor necrosis factor-blocking agents in polymyalgia rheumatica and giant cell arteritis - Reply

  Luqmani R., (2008), ANNALS OF INTERNAL MEDICINE, 148, 168 - 168

• Textbook of orthopaedics, trauma and rheumatology

  Luqmani R. et al, (2008)

• Update on the use of biologics in primary systemic vasculitides.

  Mukhtyar C. et al, (2007), Expert review of clinical immunology, 3, 901 - 911

• Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.

  Mukhtyar C. and Luqmani R., (2007), Clinical and experimental rheumatology, 25, 120 - 129

• BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.

  Lapraik C. et al, (2007), Rheumatology (Oxford, England), 46, 1615 - 1616

• Outpatient assessment of systemic vasculitis.

  Nataraja A. et al, (2007), Best practice & research. Clinical rheumatology, 21, 713 - 732

• Eular recommendations for vasculitis

  Luqmani RA. et al, (2007), ANNALS OF THE RHEUMATIC DISEASES, 66, 44 - 44

• The future of damage assessment in vasculitis.

  Seo P. et al, (2007), The Journal of rheumatology, 34, 1357 - 1371

• Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.

  Mukhtyar C. et al, (2007), Annals of the rheumatic diseases, 66, 569 - 570

• Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?

  Luqmani R., (2007), Annals of internal medicine, 146, 674 - 676

• EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

  Hellmich B. et al, (2007), Annals of the rheumatic diseases, 66, 605 - 617

• What proportion of patients in a routine clinic for rheumatoid arthritis fulfil the nice criteria for anti-TNF biologic therapy?

  Atukorala I. et al, (2007), RHEUMATOLOGY, 46, I32 - I32

• Do patients with diabetes or rheumatoid arthritis who undergo total hip arthroplasty have a worse outcome compared to patients with uncomplicated osteoarthritis?

  Manhas RS. et al, (2007), RHEUMATOLOGY, 46, I89 - I89

• Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force

  Mukhtyar CB. et al, (2007), RHEUMATOLOGY, 46, I82 - I82

• Development of comprehensive disease assessment in systemic vasculitis.

  Flossmann O. et al, (2007), Annals of the rheumatic diseases, 66, 283 - 292

• Towards diagnostic criteria for the ANCA-associated vasculitides.

  Luqmani RA., (2007), Clinical and experimental rheumatology, 25

• Prospective clinical trial of Gusperimus (deoxyspergualin) in refractory Wegener's granulomatosis

  Flossmann O. et al, (2007), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25, S111 - S111

• Long-term follow up of EUVAS studies

  Flossmann O. et al, (2007), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25, S99 - S99

• Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis

  Luqmani R. et al, (2007), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25, S117 - S117

• EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis

  Luqmani R. et al, (2007), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25, S118 - S118

• Assessment of damage in vasculitis: expert ranking of items of damage

  Seo P. et al, (2007), CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 25, S116 - S117

• Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

  Mukhtyar C. et al, (2006), Clinical and experimental rheumatology, 24

• British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years).

  Luqmani R. et al, (2006), Rheumatology (Oxford, England), 45, 1167 - 1169

• Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

  Flossmann O. et al, (2006), Annals of the rheumatic diseases, 65, 841 - 844

• Outcome in small-vessel systemic vasculitis.

  Luqmani RA. and Flossmann O., (2006), The Journal of rheumatology, 33, 1224 - 1227

• Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis

  Hellmich B. et al, (2006), ANNALS OF THE RHEUMATIC DISEASES, 65, 3 - 3

• Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).

  Deighton CM. et al, (2006), Rheumatology (Oxford, England), 45, 649 - 652

• An unusual cause of death in Wegener's granulomatosis.

  Suresh E. et al, (2006), Annals of the rheumatic diseases, 65

• The role of biologic therapies in the management of systemic vasculitis.

  Chan AT. et al, (2006), Autoimmunity reviews, 5, 273 - 278

• Calprotectin in systemic vasculitis

  Pathare SK. et al, (2006), RHEUMATOLOGY, 45, I169 - I169

• Clinical and biological assessment in systemic necrotizing vasculitides.

  Mukhtyar CB. et al, (2006), Clinical and experimental rheumatology, 24, S92 - S99

• In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype.

  Chinoy H. et al, (2006), Arthritis research & therapy, 8

• Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.

  Merkel PA. et al, (2005), The Journal of rheumatology, 32, 2488 - 2495

• Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

  Mukhtyar C. and Luqmani R., (2005), Annals of the rheumatic diseases, 64 Suppl 4, iv31 - iv36

• Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

  De Groot K. et al, (2005), Arthritis and rheumatism, 52, 2461 - 2469

• Ongoing european research initiatives in systemic vasculitides: The EUVAS program

  Luqmani RA. and Jayne D., (2005), ANNALS OF THE RHEUMATIC DISEASES, 64, 17 - 17

• Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

  Seo P. et al, (2005), Arthritis and rheumatism, 52, 2168 - 2178

• How to diagnose and treat secondary forms of vasculitis.

  Luqmani RA. et al, (2005), Best practice & research. Clinical rheumatology, 19, 321 - 336

• Acute pancreatitis with pseudocyst formation in a patient with polyarteritis nodosa.

  Suresh E. et al, (2005), The Journal of rheumatology, 32, 386 - 388

• Disease assessment in systemic vasculitis

  LUQMANI RA., (2004), APLAR Journal of Rheumatology, 7, 150 - 157

• Damage from Wegener's granulomatosis and its treatment: Prospective data from the Wegener's granulomatosis Etanercept Trial (WGET).

  Seo P. et al, (2004), ARTHRITIS AND RHEUMATISM, 50, S231 - S231

• Comparison of disease activity measures for ANCA-associated vasculitis.

  Merkel PA. et al, (2004), ARTHRITIS AND RHEUMATISM, 50, S229 - S230

• DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE

  McLaren JS. et al, (2004), RHEUMATOLOGY, 43, 110 - 111

• CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)

  Salisbury EM. et al, (2004), RHEUMATOLOGY, 43, 9 - 9

• Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis.

  de Groot K. et al, (2003), ARTHRITIS AND RHEUMATISM, 48, S660 - S660

• Complementary and alternative medicines (CAM) - Use in patients with rheumatic diseases.

  Sandhu SK. et al, (2003), ARTHRITIS AND RHEUMATISM, 48, S326 - S327

• Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)

  Salisbury EM. et al, (2003), ARTHRITIS AND RHEUMATISM, 48, S207 - S207

• The use of complementary and alternative medicines (CAM) in patients with rheumatic diseases

  Famuboni A. et al, (2003), ANNALS OF THE RHEUMATIC DISEASES, 62, 404 - 404

• Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)

  Salisbury EM. et al, (2003), ANNALS OF THE RHEUMATIC DISEASES, 62, 83 - 84

• THE USE OF THE INTERNET IN WEGENER'S GRANULOMATOSIS PATIENTS

  Kong CSM. et al, (2003), RHEUMATOLOGY, 42, 136 - 136

• INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)

  Salisbury EM. et al, (2003), RHEUMATOLOGY, 42, 135 - 135

• DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)

  McLaren JS. et al, (2003), RHEUMATOLOGY, 42, 134 - 134

• Diagnosis and assessment of systemic vasculitis.

  McLaren JS. et al, (2002), Clinical and experimental rheumatology, 20, 854 - 862

• Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis.

  Luqmani RA. et al, (2002), ARTHRITIS AND RHEUMATISM, 46, S207 - S207

• Design of the Wegener's Granulomatosis Etanercept Trial (WGET)

  Stone JH. et al, (2002), CONTROLLED CLINICAL TRIALS, 23, 450 - 468

• Measuring disease activity and outcomes in clinical studies

  Luqmani R., (2002), CLEVELAND CLINIC JOURNAL OF MEDICINE, 69, 100 - 102

• A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

  Hoffman GS. et al, (2002), Arthritis and rheumatism, 46, 1309 - 1318

• Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis

  Barlow JH. et al, (2002), Early Child Development and Care, 172, 89 - 98

• Measuring disease activity and outcomes in clinical studies.

  Luqmani R., (2002), Cleveland Clinic journal of medicine, 69 Suppl 2, SII100 - SII102

• Assessing disease activity in the systemic vasculitides.

  Luqmani RA., (2002), Current opinion in rheumatology, 14, 23 - 28

• Intensive care unit (ICU) outcomes in patients with rheumatic diseases: A retrospective multicenter, international observational study

  Dellaripa PF. et al, (2001), CRITICAL CARE MEDICINE, 29, A14 - A14

• The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting.

  McLaren JS. et al, (2001), QJM : monthly journal of the Association of Physicians, 94, 615 - 621

• Evaluation of vasculitis disease activity in Europe.

  Luqmani R., (2001), European journal of internal medicine, 12, 401 - 402

• Introduction to, and classification of, the systemic vasculitides.

  Luqmani RA. and Robinson H., (2001), Best practice & research. Clinical rheumatology, 15, 187 - 202

• Training patients to self administer sub-cutaneous methotrexate (SCMTX)

  White CR. et al, (2001), RHEUMATOLOGY, 40, 35 - 35

• Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting

  McLaren JS. et al, (2001), RHEUMATOLOGY, 40, 124 - 124

• Methotrexate (MTX) failed to control giant cell arteritis (GCA)

  Hoffman G. et al, (2001), RHEUMATOLOGY, 40, 125 - 125

• Development of a paediatric anxiety questionnaire (PAQ) in children with rheumatic diseases

  Malone P. et al, (2001), RHEUMATOLOGY, 40, 50 - 51

• Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials

  Luqmani RA. et al, (2001), RHEUMATOLOGY, 40, 80 - 80

• A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

  Stone JH. et al, (2001), Arthritis and rheumatism, 44, 912 - 920

• Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis.

  De Silva B. et al, (2000), Pediatric dermatology, 17, 480 - 483

• Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.

  Luqmani RA. et al, (2000), ARTHRITIS AND RHEUMATISM, 43, S162 - S162

• Modified Birmingham vasculitis activity score for Wegener's granulomatosis (BVAS/WG) - Construct validity.

  Maiden NL. et al, (2000), ARTHRITIS AND RHEUMATISM, 43, S367 - S367

• A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA).

  Hoffman G. et al, (2000), ARTHRITIS AND RHEUMATISM, 43, S115 - S115

• A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.

  McLaren JS. et al, (2000), ARTHRITIS AND RHEUMATISM, 43, S127 - S127

• Medical student appraisal of interactive computer-assisted learning programs embedded in a general pathology course.

  Reid WA. et al, (2000), The Journal of pathology, 191, 462 - 465

• Physiotherapy for Children with Hypermobility Syndrome

  Kerr A. et al, (2000), Physiotherapy, 86, 313 - 317

• Is it possible to offer evidence-based treatment for systemic vasculitis?

  Luqmani RA., (2000), Scandinavian journal of rheumatology, 29, 211 - 215

• Psychological health in juvenile idiopathic arthritis.

  Luqmani RA. et al, (1999), ARTHRITIS AND RHEUMATISM, 42, S229 - S229

• A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).

  Luqmani R. and Jayne D., (1999), ARTHRITIS AND RHEUMATISM, 42, S225 - S225

• Outcome in systemic vasculitis.

  Luqmani R. et al, (1998), British journal of rheumatology, 37, 1362 - 1363

• Damage is independent of disease activity in systemic vasculitis

  McRorie ER. et al, (1998), ARTHRITIS AND RHEUMATISM, 41, S115 - S115

• Optimisation of cyclophosphamide therapy in systemic vasculitis.

  Richmond R. et al, (1998), Clinical pharmacokinetics, 34, 79 - 90

• Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI).

  Exley AR. et al, (1998), British journal of rheumatology, 37, 57 - 63

• The vasculitis damage index as a surrogate outcome measure in systemic vasculitis.

  McRorie ER. et al, (1997), ARTHRITIS AND RHEUMATISM, 40, 829 - 829

• Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.

  Jayne DR. and Rasmussen N., (1997), Mayo Clinic proceedings, 72, 737 - 747

• Damage occurs early in systemic vasculitis and is an index of outcome.

  Exley AR. et al, (1997), QJM : monthly journal of the Association of Physicians, 90, 391 - 399

• Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis.

  Adu D. et al, (1997), QJM : monthly journal of the Association of Physicians, 90, 401 - 409

• Disease assessment and management of the vasculitides.

  Luqmani RA. et al, (1997), Bailliere's clinical rheumatology, 11, 423 - 446

• Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

  Exley AR. et al, (1997), Arthritis and rheumatism, 40, 371 - 380

• Rheumatoid constrictive pericarditis.

  McRorie ER. et al, (1997), Br J Rheumatol, 36, 100 - 103

• Rheumatoid constrictive pericarditis.

  McRorie ER. et al, (1997), British journal of rheumatology, 36, 100 - 103

• Rheumatoid constrictive pericarditis

  McRorie ER. et al, (1997), Revmatologiia, 36, 100 - 103

• Vasculitis integrated total assessment log (VITAL): A system for clinical evaluation of vasculitis.

  Luqmani RA. et al, (1996), ARTHRITIS AND RHEUMATISM, 39, 243 - 243

• Functional outcome vs damage in systemic vasculitis

  Exley AR. et al, (1996), ARTHRITIS AND RHEUMATISM, 39, 238 - 238

• Rheumatoid arthritis.

  Feldmann M. et al, (1996), Cell, 85, 307 - 310

• THE VASCULITIS DAMAGE INDEX (VDI)

  EXLEY A. et al, (1995), ARTHRITIS AND RHEUMATISM, 38, 1124 - 1124

• FUNCTIONAL ASSESSMENT IN VASCULITIS USING THE SF-36

  EXLEY A. et al, (1995), ARTHRITIS AND RHEUMATISM, 38, 1123 - 1123

• European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078)

  Rasmussen N. et al, (1995), Clinical & Experimental Immunology, 101, 29 - 34

• VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis.

  Bacon PA. et al, (1995), Clinical and experimental rheumatology, 13, 275 - 278

• Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis.

  Janssen BA. et al, (1994), British journal of rheumatology, 33, 1112 - 1116

• Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

  Luqmani RA. et al, (1994), QJM : monthly journal of the Association of Physicians, 87, 671 - 678

• Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis.

  Luqmani R. et al, (1994), Clinical and experimental rheumatology, 12, 503 - 508

• ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS

  ADU D. et al, (1994), JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 5, 825 - 825

• Posterior scleritis--an unusual manifestation of Cogan's syndrome.

  Shah P. et al, (1994), British journal of rheumatology, 33, 774 - 775

• Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.

  Emery P. et al, (1994), The British journal of clinical practice, 48, 82 - 86

• Classical versus non-renal Wegener's granulomatosis.

  Luqmani RA. et al, (1994), The Quarterly journal of medicine, 87, 161 - 167

• Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

  Luqmani R. et al, (1994), Drugs, 47, 259 - 285

• Treatment of vasculitis in rheumatoid arthritis.

  Luqmani RA. et al, (1994), Annales de medecine interne, 145, 566 - 576

• A severe, antineutrophil cytoplasmic antibody associated, anterior segment vasculitis.

  Talks SJ. et al, (1994), Eye (London, England), 8 ( Pt 6), 698 - 700

• Relapses in patients with a systemic vasculitis.

  Gordon M. et al, (1993), The Quarterly journal of medicine, 86, 779 - 789

• Cyclophosphamide and systemic vasculitis.

  Luqmani R. et al, (1993), The Quarterly journal of medicine, 86

• Ocular manifestations of classical and limited Wegener's granulomatosis.

  Stavrou P. et al, (1993), The Quarterly journal of medicine, 86, 719 - 725

• CONTROLLED TRIAL OF PULSE VS CONTINUOUS CYCLOPHOSPHAMIDE (CY) AND PREDNISOLONE (P) IN THE TREATMENT OF SYSTEMIC VASCULITIS

  LUQMANI R. et al, (1993), ARTHRITIS AND RHEUMATISM, 36, S96 - S96

• The validity of surrogate markers in rheumatic disease.

  Emery P. and Luqmani R., (1993), British journal of rheumatology, 32 Suppl 3, 3 - 8

• Two cases of 'Wegener's tuberculosis'.

  Gordon C. et al, (1993), British journal of rheumatology, 32, 143 - 149

• Necrotizing vasculitis--relapse despite cytotoxic therapy.

  Gordon M. et al, (1993), Advances in experimental medicine and biology, 336, 477 - 481

• THE CLINICAL-VALUE OF MEASURING SOLUBLE VCAM, E-SELECTIN AND ICAM-1 IN SLE, SYSTEMIC-SCLEROSIS AND THE SYSTEMIC VASCULITIDES

  GORDON C. et al, (1992), ARTHRITIS AND RHEUMATISM, 35, S164 - S164

• MULTIPLE JOINT INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE (IATH) IN JUVENILE CHRONIC ARTHRITIS (JCA)

  LUQMANI R. et al, (1992), ARTHRITIS AND RHEUMATISM, 35, S328 - S328

• CHRONIC DYSPAREUNIA - SJOGREN SYNDROME - ANOTHER CLINICAL PRESENTATION

  SHEERAN T. et al, (1992), BRITISH JOURNAL OF RHEUMATOLOGY, 31, 57 - 57

• Inner ear deafness in Wegener's granulomatosis.

  Luqmani R. et al, (1991), The Journal of rheumatology, 18, 766 - 768

• Azathioprine, cyclophosphamide and chlorambucil.

  Luqmani RA. et al, (1990), Bailliere's clinical rheumatology, 4, 595 - 619

• Review of UK data on the rheumatic diseases--2. Rheumatoid arthritis.

  Hazes JM. and Silman AJ., (1990), British journal of rheumatology, 29, 310 - 312

• Listeria monocytogenes infection in a prosthetic knee joint in rheumatoid arthritis.

  Booth LV. et al, (1990), Annals of the rheumatic diseases, 49, 58 - 59

• A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of rheumatoid arthritis.

  Bacon P. et al, (1990), Current medical research and opinion, 12, 121 - 127

• A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of osteoarthritis.

  Bacon P. et al, (1990), Current medical research and opinion, 12, 128 - 134

• AN HLA-DQ-BETA ASSOCIATED RESTRICTION FRAGMENT LENGTH POLYMORPHISM IN RHEUMATOID-ARTHRITIS

  HOWELL W. et al, (1988), DISEASE MARKERS, 6, 58 - 58

• Yersinia arthritis with erythema nodosum.

  Luqmani RA. and Dawes PT., (1986), Postgraduate medical journal, 62

• INHIBITION OF THROMBOXANE SYNTHESIS AND OF ARACHIDONATE-INDUCED PLATELET BEHAVIOR IN PLATELETS FROM DIFFERENT INDIVIDUALS

  HEPTINSTALL S. et al, (1981), THROMBOSIS AND HAEMOSTASIS, 46, 427 - 427

Key Publications

• Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

  Robson J. et al, (2015), Annals of the rheumatic diseases, 74, 177 - 184

• The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.

  Robson JC. et al, (2015), Annals of the rheumatic diseases, 74, 129 - 135

• A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULMOATOSIS AND MICROSCOPIC POLYANGIITIS

  Suppiah R. et al, (2010), RHEUMATOLOGY, 49, I124 - I124

• Mortality in Wegener's granulomatosis: a bimodal pattern.

  Luqmani R. et al, (2011), Rheumatology (Oxford, England), 50, 697 - 702

• Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

  Mukhtyar C. et al, (2009), Annals of the rheumatic diseases, 68, 1827 - 1832

Recent Publications

• The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.

  Luqmani R. et al, (2016), Health technology assessment (Winchester, England), 20, 1 - 238

• Giant Cell Arteritis and Takayasu Arteritis: Are they a different spectrum of the same disease?

  O'Neill L. et al, (2015), Indian Journal of Rheumatology, 10, S11 - S21

• Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.

  Robson JC. et al, (2015), The Journal of rheumatology, 42, 2204 - 2209

• The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study

  Luqmani R. et al, (2015), ARTHRITIS & RHEUMATOLOGY, 67

• Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink.

  Miller A. et al, (2015), Rheumatology (Oxford, England), 54, 1882 - 1889